Objective : A variety of treatments are available for type 2 diabetes. We have compared the lowering of HbA1c in clinical studies with a variety of treatments and compared them to the HbA1c drop with Lysulin, a nutritional supplement.
Methods : A double-blind placebo controlled study was performed with 65 type 2 diabetes patients using Lysulin. Blood chemistries were performed for 6 months.
Results : Lysulin™ is a nutraceutical tablet containing the essential containing Lysine (an essential amino acid), Vitamin C and Zinc (a mineral) as primary ingredients. Lysulin was designed to not only lower blood glucose, but to limit the glycation of proteins. This is a mechanism not targeted by any of the current type 2 medications. In humans, lysine has shown beneficial effect in lowering blood glucose as well as acting as an inhibitor of protein glycation . Furthermore, the ability of lysine to reduce the formation of glycated proteins in diabetes induced rats have also shown to delay the appearance of the late pathologies associated with protein glycation.
In a double-blind placebo-controlled study with type 2 diabetes patients, the average HbA1c drop was 1.44% . For only those who responded (11 of 17 subjects), the HbA1c drop was 1.91% . In addition, in a study with 41 volunteers, both type 1 and type 2 showed and HbA1c drop of 0.357 with just one month of Lysulin use
Discussion : Lysulin clinical study results for patients with type 2 diabetes has shown that a nutriceutical product compares very favorably to prescription drugs for type 2 diabetes without any observed side effects. Further clinical studies are underway to confirm these results in patients with prediabetes and both adults and adolescents with type 2 diabetes.
Conclusion : A nutraceutical product performs as well or better than type 2 prescription drugs without any observed side effects.
John Burd– ceo, Lysulin, Inc., San Diego, California
San Diego, California
Dr. Burd is Founder & CEO of Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patent pending product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. Dr. Burd was also the cofounder of Sabur Technology, Inc., developing a new non-invasive continuous glucose monitoring technology. Prior to Sabur, Dr. Burd was Founder and CEO of Oculir, Inc., a General Partner of Windamere Venture Partners and Chairman & CEO of MiraMedica, a company developing computer-aided detection technology for enhanced cancer diagnosis. MiraMedica was sold to Kodak in August 2003. Dr. Burd was previously President & CEO of DexCom, where he directed the company’s work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2018 DexCom had a market cap of over $11 billion.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duet Diabetes Control System to healthcare professionals and the In Charge Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician’s office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company’s operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 40 articles and his work in the medical and biotechnology field has led to the filing and ownership of twenty-three patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.